Zealand Pharma wins positive CHMP opinion for Zeydovio in short bowel syndrome
CHMP issued a positive opinion recommending EU marketing authorization for Zeydovio (glepaglutide) for adults with short bowel syndrome; European Commission decision expected in ~67 days.
Zealand Pharma A/S said the CHMP issued a positive opinion recommending EU marketing authorization for Zeydovio, also known as glepaglutide, for the treatment of adults with short bowel syndrome. The European Commission decision is expected in approximately 67 days.